PUBLISHER: Grand View Research | PRODUCT CODE: 2132278
PUBLISHER: Grand View Research | PRODUCT CODE: 2132278
The global corneal cross linking devices market size was valued at USD 151.7 million in 2025 and is projected to grow from USD 163.5 million in 2026 to USD 279.4 million by 2033, at a CAGR of 8.0% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 43.4% in 2025. The global market is experiencing strong growth, driven by the increasing prevalence and diagnosis of keratoconus and other corneal ectatic disorders.
Greater awareness of early disease detection and the clinical benefits of corneal cross-linking are encouraging the adoption of these procedures. Technological advancements, including accelerated and epithelium-on cross-linking systems, are improving treatment efficiency and patient convenience. The market is also benefiting from the expansion of ophthalmic infrastructure and the increasing availability of specialized corneal care.
The corneal cross-linking devices industry is entering an important phase of development as rising awareness of keratoconus, improved diagnosis, and technological advances in cross-linking procedures expand the addressable patient population. Corneal cross-linking is primarily used to strengthen the cornea and slow or halt the progression of keratoconus, a progressive disorder characterized by thinning and weakening of the cornea. Unlike spectacles and contact lenses, which primarily correct the resulting visual impairment, CXL targets the underlying biomechanical instability of the cornea.
The market is particularly attractive because keratoconus frequently affects younger individuals, creating a substantial long-term clinical burden. A recent systematic review and meta-analysis published in Cornea estimated global keratoconus prevalence at 289.1 cases per 100,000 people, equivalent to approximately 0.24% of the population, and concluded that more than 23.7 million people globally are affected. The study also found that prevalence and incidence were highest among people aged 20-29 years and that prevalence was particularly high in South Asia, West Asia, and Africa.
The commercial opportunity therefore, extends beyond simply replacing existing UV-A systems. The introduction of epi-on therapy could increase patient willingness to undergo treatment, particularly among patients who may be reluctant to undergo epithelial removal. Reimbursement represents a major determinant of CXL adoption because treatment requires specialized equipment, trained ophthalmologists, and procedure-specific products.
The U.S. market has recently received an important reimbursement development. In April 2026, Glaukos announced that CMS had assigned a permanent HCPCS J-code, J2789, to Epioxa, effective July 1, 2026. The company stated that the product-specific code is expected to streamline reporting and payment and support market access initiatives. This development is important because regulatory approval alone does not guarantee commercial adoption. Physicians and facilities need a viable pathway for reimbursement, while patients need reasonable access to the treatment.
Global Corneal Cross Linking Devices Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global corneal cross linking devices market report based on product, application, end use, and region: